The current status of renal anemia treatment is still not ideal, and innovative solutions are urgently needed in clinical practice

The prevalence of chronic kidney disease in China accounts for approximately 10.

The incidence of renal anemia continues to increase with the progress of CKD

The kidney is an important endocrine organ of the human body and the main source of erythropoietin (EPO).

Another important mechanism of renal anemia is iron deficiency anemia caused by iron deficiency.

Therefore, the occurrence of renal anemia is closely related to the degree of kidney damage.

Once anemia occurs, it will in turn accelerate the progression of kidney disease.

Existing treatment options fail to fully meet the needs of patients

At present, the main drug treatments for renal anemia are erythropoiesis stimulants (ESA), iron, and hypoxia inducible factor prolyl hydroxylase inhibitors (HIF-PHI).

Since most CDK patients have varying degrees of anemia, patients need to dynamically understand the changes in their hemoglobin levels in time, and appropriate nutrition supplements.

Among them, iron treatment mainly includes oral iron supplementation and intravenous iron supplementation.

The "Chinese Expert Consensus on Intravenous Iron Application" (2019) pointed out that intravenous iron is currently the standard treatment for patients with chronic kidney disease on dialysis and non-dialysis.

Professor Hao Chuanming, director of the Department of Nephrology, Huashan Hospital Affiliated to Fudan University, believes that intravenous iron supplementation should be routinely used for peritoneal dialysis patients and hemodialysis patients, and high-dose active iron supplementation is better than lower-dose passive iron supplementation, which can significantly reduce deaths.

"Especially for patients with uremia, the intestinal absorption function is extremely poor, and oral iron is basically ineffective.

In the initial treatment phase of intravenous iron supplementation, the dose of iron sucrose or iron dextran is usually 1000 mg for a course of treatment.

High-dose iron injection is on the market, safer and more convenient

Recently, the innovative drug Monofi (Isomalt Iron 1000) was officially launched in China.

The drug has a unique and innovative matrix structure that can tightly bind iron atoms and stably control iron release.

It is worth mentioning that compared with the traditional iron cane sugar, Monofi? The onset of action is faster and the safety is better.

"The new generation of high-dose injection iron is formed by complexing linear isomaltose anhydride with iron to ensure stable control of iron release.

Professor Chen Nan, director of the Department of Nephrology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, said that iron isomalt contains no reducing sugar units and has low immunogenicity.
Compared with branched-chain polysaccharides, it is less prone to allergic reactions, which means that allergic tests are not required.
1000mg-2000mg (no more than 20mg/kg body weight) can be instilled once, and the infusion only takes 15-30 minutes, which is more convenient to use, which greatly improves the patient's treatment compliance.

Based on significant clinical treatment advantages, Monofi? It was approved in Europe in 2009 and has been marketed in more than 30 countries and regions including the United States and the European Union.
It is approved for the treatment of iron-deficiency/iron-deficiency anemia.
Its efficacy and safety have been clinically used for more than 18 million doses.
The verification, now Monofi? The listing of CKD in China will bring innovative solutions to iron supplementation for CKD patients, and promote the further improvement of the management level of renal anemia in China.